EMAIL THIS PAGE TO A FRIEND

PLoS neglected tropical diseases

An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.


PMID 26135599

Abstract

Dengue virus (DENV), a global disease, is divided into four serotypes (DENV1-4). Cross-reactive and non-neutralizing antibodies against envelope (E) protein of DENV bind to the Fcγ receptors (FcγR) of cells, and thereby exacerbate viral infection by heterologous serotypes via antibody-dependent enhancement (ADE). Identification and modification of enhancing epitopes may mitigate enhancement of DENV infection. In this study, we characterized the cross-reactive DB21-6 and DB39-2 monoclonal antibodies (mAbs) against domain I-II of DENV; these antibodies poorly neutralized and potently enhanced DENV infection both in vitro and in vivo. In addition, two enhancing mAbs, DB21-6 and DB39-2, were observed to compete with sera antibodies from patients infected with dengue. The epitopes of these enhancing mAbs were identified using phage display, structural prediction, and mapping of virus-like particle (VLP) mutants. N8, R9, V12, and E13 are the reactive residues of DB21-6, while N8, R9, and E13 are the reactive residues of DB39-2. N8 substitution tends to maintain VLP secretion, and decreases the binding activity of DB21-6 and DB39-2. The immunized sera from N8 substitution (N8R) DNA vaccine exerted greater neutralizing and protective activity than wild-type (WT)-immunized sera, both in vitro and in vivo. Furthermore, treatment with N8R-immunized sera reduced the enhancement of mortality in AG129 mice. These results support identification and substitution of enhancing epitope as a novel strategy for developing safe dengue vaccines.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB3701274
Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701284 Anti-Human IgG (Fc specific), highly cross adsorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701289 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
I9885 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701314 Anti-Human IgG (H+L), F(ab) fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701247 Anti-Human IgG F(ab′)2 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701246 Anti-Human IgG F(ab′)2, F(ab′)2 fragment, highly cross absorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
P5412
o-Phenylenediamine, tablet, 20 mg substrate per tablet
C6H8N2
P9029
o-Phenylenediamine, Peroxidase substrate, ≥98.0%, powder
C6H8N2
P23938
o-Phenylenediamine, flaked, 99.5%
C6H8N2
694975
o-Phenylenediamine, sublimed, ≥99%
C6H8N2
P6662
o-Phenylenediamine dihydrochloride, tablet, 1 mg substrate per tablet
C6H8N2 · 2HCl
P6787
o-Phenylenediamine dihydrochloride, tablet, 2 mg substrate per tablet
C6H8N2 · 2HCl
P8806
o-Phenylenediamine dihydrochloride, tablet, 3 mg substrate per tablet
C6H8N2 · 2HCl
P8787
o-Phenylenediamine dihydrochloride, tablet, 4 mg substrate per tablet
C6H8N2 · 2HCl
P3804
o-Phenylenediamine dihydrochloride, tablet, 5 mg substrate per tablet
C6H8N2 · 2HCl
P6912
o-Phenylenediamine dihydrochloride, tablet, 5 mg substrate per tablet
C6H8N2 · 2HCl
P8287
o-Phenylenediamine dihydrochloride, tablet, 10 mg substrate per tablet
C6H8N2 · 2HCl
P4664
o-Phenylenediamine dihydrochloride, tablet, 15 mg substrate per tablet
C6H8N2 · 2HCl
P7288
o-Phenylenediamine dihydrochloride, tablet, 20 mg substrate per tablet
C6H8N2 · 2HCl
P8412
o-Phenylenediamine dihydrochloride, tablet, 30 mg substrate per tablet
C6H8N2 · 2HCl
P1063
o-Phenylenediamine dihydrochloride, tablet, 60 mg substrate per tablet
C6H8N2 · 2HCl
P1526
o-Phenylenediamine dihydrochloride, peroxidase substrate
C6H8N2 · 2HCl
S0266
Spermidine, BioReagent, for molecular biology, suitable for cell culture, ≥98%
C7H19N3
S2626
Spermidine, ≥99% (GC)
C7H19N3
S4139
Spermidine, suitable for cell culture, BioReagent
C7H19N3
85558
Spermidine, BioUltra, for molecular biology, ≥99.5% (GC)
C7H19N3